Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

PURPOSE: Mucosal melanoma is an aggressive malignancy with a poor response to conventional therapies. The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor), have not been reported...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: D’Angelo, Sandra P., Larkin, James, Sosman, Jeffrey A., Lebbé, Celeste, Brady, Benjamin, Neyns, Bart, Schmidt, Henrik, Hassel, Jessica C., Hodi, F. Stephen, Lorigan, Paul, Savage, Kerry J., Miller, Wilson H., Mohr, Peter, Marquez-Rodas, Ivan, Charles, Julie, Kaatz, Martin, Sznol, Mario, Weber, Jeffrey S., Shoushtari, Alexander N., Ruisi, Mary, Jiang, Joel, Wolchok, Jedd D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2017
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559888/
https://ncbi.nlm.nih.gov/pubmed/28056206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.9258
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge